Latest News From Lumira Ventures

Notch Therapeutics Announces R&D Collaboration with Allogene worth up to $283M per Target

Jennifer Schram Main Page, Notch Therapeutics, Portfolio News, Press Release

SOUTH SAN FRANCISCO, Calif. and TORONTO — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, …

Lumira Joins Financing Syndicate for Notch Therapeutics – a New Company with Revolutionary Allogeneic T Cell Technology

Jennifer Schram Lumira News, Notch Therapeutics, Portfolio News, Press Release

Toronto, ON, (GLOBE NEWSWIRE) — Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, …

Aurinia Completes Last Patient Study Visit in AURORA Phase 3 Lupus Nephritis Study & Provides Update on ATM Facility

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today reported that the last patient study visit has …